financetom
Business
financetom
/
Business
/
Sachem Capital Appoints Nicholas Marcello as Interim Chief Financial Officer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sachem Capital Appoints Nicholas Marcello as Interim Chief Financial Officer
Jun 6, 2024 2:48 PM

05:22 PM EDT, 06/06/2024 (MT Newswires) -- Sachem Capital ( SACH ) said Thursday it appointed Nicholas M. Marcello as interim chief financial officer, effective immediately.

Chief Executive John Villano was serving as interim chief financial officer in an additional role before Marcello's appointment, according to the company.

Marcello most recently was the vice president of finance and operations at Sachem Capital ( SACH ).

Price: 3.0500, Change: +0.01, Percent Change: +0.33

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vivos Therapeutics Files Registration Statement for Secondary Sale of Securities
Vivos Therapeutics Files Registration Statement for Secondary Sale of Securities
Jul 30, 2024
01:54 PM EDT, 07/30/2024 (MT Newswires) -- Vivos Therapeutics ( VVOS ) filed a registration statement Tuesday for the sale of common stock, pre-funded warrant, and share purchase warrant by a selling shareholder. The statement covers the sale of 169,498 shares, pre-funded warrant to buy over 3 million common shares in the company, and purchase warrant to buy up to...
Fractyl Health Gets FDA Breakthrough Device Designation for Weight Maintenance Procedure
Fractyl Health Gets FDA Breakthrough Device Designation for Weight Maintenance Procedure
Jul 30, 2024
01:52 PM EDT, 07/30/2024 (MT Newswires) -- Fractyl Health ( GUTS ) said Tuesday its Revita system for use in maintaining weight loss after the discontinuation of GLP-1 drugs has received breakthrough device designation from the US Food and Drug Administration. The company said the designation will expedite review with the FDA upon successful completion of a pivotal study of...
--Street Color: Stellantis Reportedly Planning for Further Job Cuts in US Through Voluntary Buyout
--Street Color: Stellantis Reportedly Planning for Further Job Cuts in US Through Voluntary Buyout
Jul 30, 2024
01:56 PM EDT, 07/30/2024 (MT Newswires) -- Price: 16.74, Change: -0.25, Percent Change: -1.47 ...
Intellia Therapeutics Receives Backing of UK Health Regulator to Conduct Trial of Gene Therapy
Intellia Therapeutics Receives Backing of UK Health Regulator to Conduct Trial of Gene Therapy
Jul 30, 2024
01:58 PM EDT, 07/30/2024 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Tuesday it received the backing of UK's health regulator to conduct a clinical trial of its gene therapy NTLA-3001. The country's Medicine and Healthcare products Regulatory Agency approved the company's phase 1/2 study to evaluate the gene editing treatment for a rare, genetic condition known as alpha-1...
Copyright 2023-2026 - www.financetom.com All Rights Reserved